Synapsoft logo
AI Insights from Disclosures
Searching...
Kolon TissueGene, Inc. 950160
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Kolon TissueGene, Inc. is a company that develops new drugs using its cell and gene technology, the TG-C Platform, and obtained a U.S. patent for 'gene therapy using TGF-β1' in September 2004. As of the report submission date, the company is conducting an FDA Phase 3 clinical trial for the knee osteoarthritis (Knee OA) indication, and has received FDA approval for a Phase 2 clinical trial for the hip osteoarthritis (Hip OA) indication.
Representative Director Jeon Seungho
Founded June 9, 1999
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number -
Business number 201-74-063267
Phone Number 1-301-921-6000
Fax Number
Website tissuegene.com
Company Address Rockville, MD, USA 9713 Key West Ave Suite 300
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant